C-KIT expression in primary cutaneous T-cell lymphomas

Journal of Cutaneous Pathology

Volumn 31, Issue 9, 2004, Pages 577-582

  Brauns, Tilmann C ^a   Schultewolter, Thomas ^a   Dissemond, Joachim ^a   Maschke, Jan ^a   Goos, Manfred ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ARTICLE; CELL POPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; MAST CELL; PROTEIN EXPRESSION; SKIN LYMPHOMA; T CELL LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE-CELL; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 4544271179     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2004.00182.x     Document Type: Article

References (22)

1. Gadd SJ, Ashman LK. A murine monoclonal antibody specific for a cell-surface antigen expressed by a subgroup of human myeloid leukaemias. Leuk Res 1985; 9: 1329.
2. Ashman LK, Gadd SJ, Mayrhofer G, Spargo LDJ, Cole SR. A murine monoclonal antibody to an acute myeloid leukaemia-associated cell surface antigen identifies tissue mast cells. In McMichael AJ, ed. Leukocyte Typing III White Cell Differentiation Antigens. Oxford: Oxford University Press, 1987; 726.
3. Cambareri AC, Ashman LK, Cole SR, Lyons AB. A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro. Leuk Res 1988; 12: 929.
4. Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA. Expression of the YB5.B8 antigen (C-KIT proto-oncogene product) in normal human bone marrow. Blood 1991; 78: 30.
5. Papayannopoulou T, Brice M, Broudy VC, Zsebo KM. Isolation of C-KIT receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile. Blood 1991; 78: 1403.
6. Avraham H, Vannier E, Cowley S, et al. Effects of the stem cell factor, C-KIT ligand, on human megakaryocytic cells. Blood 1992; 79: 365.
7. Mayrhofer G, Gadd SJ, Spargo LD, Ashman LK. Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues. Immunol Cell Biol 1987; 65: 241.
8. Ashman LK. The biology of stem cell factor and its receptor C-KIT. Int J Biochem Cell Biol 1999; 31: 1037.
9. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345.
10. Lyman SD, Jacobsen SE. C-KIT ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101.
11. Hongyo T, Li T, Syaifudin M, et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res 2000; 60: 2345.
12. Aldínucci D, Poletto D, Nanni P, et al. Hodgkin and Reed-Sternberg cells express functional C-KIT receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002; 118: 1055.
13. + anaplastic large cell lymphomas. Blood 1994; 83: 785.
14. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100.
15. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947.
16. Heinrich MC, Griffith DJ, et al. Inhibition of C-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925.
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472.
18. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354.
19. Aldinucci D, Poletto D, Nanni P, et al. Hodgkin and Reed-Sternberg cells express functional C-KIT receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002; 118: 1055.
20. Ottmann OG, Wassmann B, Hoelzer D. Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase. (Glivec) Med Klin 2002; 97: 16.
21. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530.
22. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928.